NCT01073891 - Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

January 31, 2011

Conditions

Healthy

Interventions

DRUG

Moxifloxacin (Avelox, BAY12-8039)

Single oral dose of moxifloxacin (Avelox, BAY12-8039) IR (immediate release) tablet 400 mg under fasting conditions

DRUG

Moxifloxacin (BAY12-8039)

Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fasting conditions

DRUG

Moxifloxacin (BAY12-8039)

Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fed conditions

Trial Locations (1)

Wuppertal